Gilead Historical Cash Flow
| GILD Stock | USD 66.93 0.38 0.56% |
Analysis of Gilead Sciences cash flow over time is an excellent tool to project Gilead Sciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 3.5 B or Other Cashflows From Financing Activities of 2.3 B as it is a great indicator of Gilead Sciences ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Gilead Sciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Gilead Sciences is a good buy for the upcoming year.
Gilead |
About Gilead Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Gilead balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Gilead's non-liquid assets can be easily converted into cash.
Gilead Sciences Cash Flow Chart
Gilead Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the Gilead Sciences Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
At present, Gilead Sciences' Other Cashflows From Financing Activities is projected to decrease significantly based on the last few years of reporting. The current year's Depreciation is expected to grow to about 2.8 B, whereas Change In Working Capital is projected to grow to (2.2 B). Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Gilead Sciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Gilead Sciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Gilead Sciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Gilead Sciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.At present, Gilead Sciences' Other Cashflows From Financing Activities is projected to decrease significantly based on the last few years of reporting. The current year's Depreciation is expected to grow to about 2.8 B, whereas Change In Working Capital is projected to grow to (2.2 B).
Gilead Sciences cash flow statement Correlations
Click cells to compare fundamentals
Gilead Sciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Gilead Sciences cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (6.3B) | (5.6B) | (659M) | 74M | 673M | 706.7M | |
| Free Cash Flow | 8.3B | 7.5B | 10.8B | 8.3B | 7.4B | 4.2B | |
| Change In Working Capital | (798M) | (1.6B) | 489M | (1.8B) | (2.3B) | (2.2B) | |
| Begin Period Cash Flow | 17.9B | 11.6B | 6.0B | 5.3B | 5.4B | 3.5B | |
| Other Cashflows From Financing Activities | (122M) | 8.0B | (145M) | (173M) | 1.7B | 2.3B | |
| Depreciation | 1.4B | 1.5B | 2.1B | 2.1B | 2.7B | 2.8B | |
| Other Non Cash Items | 4.6B | 7.8B | 2.1B | 5.1B | 2.2B | 2.3B | |
| Capital Expenditures | 825M | 650M | 579M | 728M | 585M | 614.3M | |
| Total Cash From Operating Activities | 9.1B | 8.2B | 11.4B | 9.1B | 8.0B | 4.5B | |
| Net Income | 5.4B | 89M | 6.2B | 4.6B | 5.6B | 3.0B | |
| Total Cash From Financing Activities | (7.6B) | 770M | (8.9B) | (6.5B) | (5.1B) | (4.9B) | |
| End Period Cash Flow | 11.6B | 6.0B | 5.3B | 5.4B | 6.1B | 3.7B | |
| Change To Inventory | (310M) | (95M) | (195M) | 11M | (842M) | (799.9M) | |
| Change To Liabilities | (178M) | (58M) | 207M | (1.1B) | (1.3B) | (1.2B) | |
| Stock Based Compensation | 636M | 643M | 635M | 637M | 766M | 422.3M | |
| Total Cashflows From Investing Activities | (7.8B) | (14.6B) | (3.1B) | (2.5B) | (2.3B) | (2.4B) | |
| Change To Account Receivables | (218M) | (1.2B) | 313M | (406M) | 157M | 164.9M | |
| Other Cashflows From Investing Activities | (4.7B) | (25.9B) | (3.1B) | (1.8B) | (1.6B) | (1.7B) | |
| Change To Netincome | (478M) | 6.5B | 11.4B | 3.5B | 4.0B | 4.2B | |
| Sale Purchase Of Stock | (1.7B) | (1.6B) | (546M) | (1.4B) | (1B) | (1.1B) | |
| Investments | (2.3B) | 11.9B | (3.1B) | (2.5B) | (1.9B) | (1.8B) | |
| Change Receivables | (218M) | (1.2B) | 313M | (406M) | (466.9M) | (490.2M) | |
| Net Borrowings | (2.8B) | 5.7B | (4.8B) | (1.5B) | (1.4B) | (1.3B) | |
| Dividends Paid | 3.2B | 3.4B | 3.6B | 3.7B | (3.8B) | (3.6B) | |
| Cash And Cash Equivalents Changes | (6.3B) | (5.7B) | (624M) | 137M | 123.3M | 229.1M | |
| Cash Flows Other Operating | 3.3B | 1.5B | 689M | 727M | 836.1M | 664.3M | |
| Change To Operating Activities | (696M) | 426M | 647M | (705M) | (634.5M) | (602.8M) | |
| Issuance Of Capital Stock | 209M | 256M | 169M | 309M | 382M | 295.9M |
Gilead Sciences Investors Sentiment
The influence of Gilead Sciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Gilead. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Gilead Sciences' public news can be used to forecast risks associated with an investment in Gilead. The trend in average sentiment can be used to explain how an investor holding Gilead can time the market purely based on public headlines and social activities around Gilead Sciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Gilead Sciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Gilead Sciences' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Gilead Sciences' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Gilead Sciences.
Gilead Sciences Implied Volatility | 62.11 |
Gilead Sciences' implied volatility exposes the market's sentiment of Gilead Sciences stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Gilead Sciences' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Gilead Sciences stock will not fluctuate a lot when Gilead Sciences' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Gilead Sciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Gilead Sciences' short interest history, or implied volatility extrapolated from Gilead Sciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Dividend Share 3 | Earnings Share 4.5 | Revenue Per Share 21.728 | Quarterly Revenue Growth (0.04) |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.